| Autor: |
Papp, A., Gao, Y., Wei, L., Li, J., Wang, D., Socinski, M. A., Aimiuwu, J., Hicks, W. J., Zhao, W., Otterson, G. A., Blachly, J. S., Stinchcombe, T. E., Poi, M., Villalona-Calero, M. A., Schaaf, L. J., Starrett, S. L., Phelps, M. A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Předmět: |
|
| DOI: |
10.17615/05ak-3t14 |
| Popis: |
Prospective studies focusing on EGFR inhibitors in African Americans with NSCLC have not been previously performed. In this phase II randomized study, 55 African Americans with NSCLC received erlotinib 150mg/day or a body weight adjusted dose with subsequent escalations to the maximum allowable, 200mg/day, to achieve rash. Erlotinib and OSI-420 exposures were lower compared to previous reports, consistent with CYP3A pharmacogenetics implying higher metabolic activity. Tumor genetics revealed only two EGFR mutations, EGFR amplification in 17/47 samples, 8 KRAS mutations and 5 EML4-ALK translocations. Although absence of rash was associated with shorter time to progression (TTP), disease control rate, TTP, and 1-year survival were not different between the two dose groups, indicating the dose-to-rash strategy failed to increase clinical benefit. Observed low incidence of toxicity and low erlotinib exposure suggest standardized and maximum allowable dosing may be suboptimal in African Americans. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
